Murine Animal Models in Osteogenesis Imperfecta: The Quest for Improving the Quality of Life

被引:5
作者
Alcorta-Sevillano, Natividad [1 ,2 ]
Infante, Arantza [1 ]
Macias, Iratxe [1 ]
Rodriguez, Clara, I [1 ]
机构
[1] Cruces Univ Hosp, Biocruces Bizkaia Hlth Res Inst, Stem Cells & Cell Therapy Lab, Plaza Cruces S-N, Baracaldo 48903, Spain
[2] Univ Basque Country, Dept Cell Biol & Histol, UPV EHU, Leioa 48940, Spain
关键词
osteogenesis imperfecta; murine models; new therapies; preclinical studies; in vivo; bone; parameters; fragility; MESENCHYMAL STEM-CELLS; SCLEROSTIN ANTIBODY TREATMENT; BONE-MARROW-TRANSPLANTATION; PLUS MOUSE MODEL; IN-UTERO TRANSPLANTATION; COLLAGEN CROSS-LINKING; ALENDRONATE TREATMENT; PROLYL; 3-HYDROXYLATION; PERINATAL LETHALITY; CLINICAL-FEATURES;
D O I
10.3390/ijms24010184
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Osteogenesis imperfecta is a rare genetic disorder characterized by bone fragility, due to alterations in the type I collagen molecule. It is a very heterogeneous disease, both genetically and phenotypically, with a high variability of clinical phenotypes, ranging from mild to severe forms, the most extreme cases being perinatal lethal. There is no curative treatment for OI, and so great efforts are being made in order to develop effective therapies. In these attempts, the in vivo preclinical studies are of paramount importance; therefore, serious analysis is required to choose the right murine OI model able to emulate as closely as possible the disease of the target OI population. In this review, we summarize the features of OI murine models that have been used for preclinical studies until today, together with recently developed new murine models. The bone parameters that are usually evaluated in order to determine the relevance of new developing therapies are exposed, and finally, current and innovative therapeutic strategies attempts considered in murine OI models, along with their mechanism of action, are reviewed. This review aims to summarize the in vivo studies developed in murine models available in the field of OI to date, in order to help the scientific community choose the most accurate OI murine model when developing new therapeutic strategies capable of improving the quality of life.
引用
收藏
页数:31
相关论文
共 180 条
  • [11] 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
    Bone, Henry G.
    Wagman, Rachel B.
    Brandi, Maria L.
    Brown, Jacques P.
    Chapurlat, Roland
    Cummings, Steven R.
    Czerwinski, Edward
    Fahrleitner-Pammer, Astrid
    Kendler, David L.
    Lippuner, Kurt
    Reginster, Jean-Yves
    Roux, Christian
    Malouf, Jorge
    Bradley, Michelle N.
    Daizadeh, Nadia S.
    Wang, Andrea
    Dakin, Paula
    Pannacciulli, Nicola
    Dempster, David W.
    Papapoulos, Socrates
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (07) : 513 - 523
  • [12] Effects of treatment with a bone-targeted prostaglandin E2 receptor 4 agonist C3 (Mes-1007) in a mouse model of severe osteogenesis imperfecta
    Boraschi-Diaz, Iris
    Chen, Gang
    Polak-Nachumow, Jonathan
    Young, Robert N.
    Rauch, Frank
    [J]. BONE, 2021, 145
  • [13] Metabolic phenotype in the mouse model of osteogenesis imperfecta
    Boraschi-Diaz, Iris
    Tauer, Josephine T.
    El-Rifai, Omar
    Guillemette, Delphine
    Lefebvre, Genevieve
    Rauch, Frank
    Ferron, Mathieu
    Komarova, Svetlana V.
    [J]. JOURNAL OF ENDOCRINOLOGY, 2017, 234 (03) : 279 - 289
  • [14] Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?
    Boskey, Adele L.
    Marino, Josephine
    Spevak, Lyudmila
    Pleshko, Nancy
    Doty, Stephen
    Carter, Erin M.
    Raggio, Cathleen L.
    [J]. CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2015, 473 (08) : 2587 - 2598
  • [15] Osteogenesis Imperfecta: Current and Prospective Therapies
    Botor, Malwina
    Fus-Kujawa, Agnieszka
    Uroczynska, Marta
    Stepien, Karolina L.
    Galicka, Anna
    Gawron, Katarzyna
    Sieron, Aleksander L.
    [J]. BIOMOLECULES, 2021, 11 (10)
  • [16] Guidelines for Assessment of Bone Microstructure in Rodents Using Micro-Computed Tomography
    Bouxsein, Mary L.
    Boyd, Stephen K.
    Christiansen, Blaine A.
    Guldberg, Robert E.
    Jepsen, Karl J.
    Mueller, Ralph
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2010, 25 (07) : 1468 - 1486
  • [17] Effects of the activin A-myostatin-follistatin system on aging bone and muscle progenitor cells
    Bowser, Matthew
    Herberg, Samuel
    Arounleut, Phonepasong
    Shi, Xingming
    Fulzele, Sadanand
    Hill, William D.
    Isales, Carlos M.
    Hamrick, Mark W.
    [J]. EXPERIMENTAL GERONTOLOGY, 2013, 48 (02) : 290 - 297
  • [18] High proportion of mutant osteoblasts is compatible with normal skeletal function in mosaic carriers of osteogenesis imperfecta
    Cabral, WA
    Marini, JC
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2004, 74 (04) : 752 - 760
  • [19] A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta
    Camacho, NP
    Raggio, CL
    Doty, SB
    Root, L
    Zraick, V
    Ilg, WA
    Toledano, TR
    Boskey, AL
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2001, 69 (02) : 94 - 101
  • [20] Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse
    Cardinal, Mickael
    Chretien, Antoine
    Roels, Thomas
    Lafont, Sebastien
    Ominsky, Michael S.
    Devogelaer, Jean-Pierre
    Manicourt, Daniel H.
    Behets, Catherine
    [J]. FRONTIERS IN GENETICS, 2021, 12